Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 14

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 14
---
 be given that our application will be approved or that a trading 
 market will develop.                                                                                                                   |

The number of the Ordinary Shares to be issued and outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby are sold, and is based on 1,571,752 Ordinary Shares issued and outstanding as of the date of this prospectus. After giving effect to a -for- Reverse Split of our Ordinary Shares, this number excludes:

| ● | 66,946 Ordinary Shares                                                                        
 issuable upon the exercise of warrants currently outstanding, at an exercise price of $38.01; |

| ● | 31,716 Ordinary Shares                                                                                                           
 issuable upon the exercise of options to consultants under our incentive option plan outstanding as of such date, at an exercise 
 price of $9.933, of which 31,716 were vested as of such date;                                                                    |

| ● | 194,098 Ordinary Shares                                                                                                           
 issuable upon the exercise of options to be issued to the chairman of the board of directors upon the completion of this offering 
 under our incentive option plan, at an exercise price of NIS 0.01;                                                                |

| ● | 80,355 Ordinary Shares                                                                                                             
 issuable upon the exercise of options to be issued to consultants and certain investors upon the completion of this offering under 
 our incentive option plan, at an exercise price of NIS 0.01;                                                                       |

| ● | warrants issuable to the                                                                                                           
 Bridge Loan (as defined below) lenders to purchase such number of Ordinary Shares equal to two times the respective loan amount of 
 each Bridge Loan due to such lenders, based on a price per share equal to 75.0% of the lowest price per Ordinary Share during the  
 first five trading days following the consummation of this offering; and                                                           |

| ● | warrants issuable to the                                                                                                           
 2024 Loan Agreements (as defined below) lenders to purchase such number of Ordinary Shares equal to two times the respective loan  
 amount of each 2024 Loan Agreement due to such lenders, based on a price per share equal to 75.0% of the lowest price per Ordinary 
 Share during the first five trading days following the consummation of this offering.                                              |

Unless otherwise indicated, all information in this prospectus assumes or gives effect to:

| ● | no exercise of the Representative’s’ 
 over-allotment option;               |

| ● | no exercise of Representative’s 
 Warrants